Cargando...
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...
Gardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/ https://ncbi.nlm.nih.gov/pubmed/27582886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|